首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3393239篇
  免费   252280篇
  国内免费   5027篇
耳鼻咽喉   47238篇
儿科学   111371篇
妇产科学   93995篇
基础医学   492677篇
口腔科学   97017篇
临床医学   306969篇
内科学   650602篇
皮肤病学   74201篇
神经病学   270893篇
特种医学   129456篇
外国民族医学   904篇
外科学   509745篇
综合类   76681篇
现状与发展   13篇
一般理论   1308篇
预防医学   268183篇
眼科学   79507篇
药学   254170篇
  13篇
中国医学   6360篇
肿瘤学   179243篇
  2018年   35894篇
  2017年   27343篇
  2016年   30643篇
  2015年   34831篇
  2014年   48967篇
  2013年   74158篇
  2012年   101423篇
  2011年   107740篇
  2010年   63978篇
  2009年   60649篇
  2008年   101721篇
  2007年   108123篇
  2006年   109303篇
  2005年   106375篇
  2004年   102887篇
  2003年   98535篇
  2002年   96152篇
  2001年   151387篇
  2000年   156128篇
  1999年   132065篇
  1998年   38451篇
  1997年   34062篇
  1996年   34041篇
  1995年   32580篇
  1994年   30270篇
  1993年   28593篇
  1992年   105669篇
  1991年   103294篇
  1990年   100918篇
  1989年   97527篇
  1988年   90296篇
  1987年   88643篇
  1986年   83813篇
  1985年   80716篇
  1984年   60521篇
  1983年   51920篇
  1982年   30838篇
  1981年   27814篇
  1979年   56884篇
  1978年   40285篇
  1977年   33815篇
  1976年   32234篇
  1975年   34449篇
  1974年   41673篇
  1973年   39881篇
  1972年   37211篇
  1971年   35127篇
  1970年   32410篇
  1969年   30781篇
  1968年   28137篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
A 42‐year‐old man presented with a viral prodrome and tested positive for influenza A. He rapidly deteriorated developing cardiogenic shock, rhabdomyolysis, and acute kidney injury. Patient improved 1 week later with supportive measures including vasopressors, inotropes, and an intraaortic balloon pump. We report this case as it highlights the discordance between echocardiographic ventricular wall thickening as a result of myocardial edema, and electrocardiographic findings at presentation, with a reversal in findings at time of resolution. Additionally, there was some suggestion of a regional pattern to the reduced longitudinal strain.  相似文献   
82.
83.
84.
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence underpinning our management of osteoporosis still exist. Evidence of antifracture efficacy in the groups of patients who most commonly use calcium and vitamin D supplements is lacking, the safety of calcium supplements is in doubt, and the safety and efficacy of high doses of vitamin D give cause for concern. Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures. However, most trials provide little information regarding long‐term efficacy or safety. A particular concern at present is the possibility that oral bisphosphonates might cause atypical femoral fractures. Observational data suggest that the incidence of this type of fracture increases steeply with duration of bisphosphonate use, resulting in concern that the benefit–risk balance may become negative in the long term, particularly in patients in whom the osteoporotic fracture risk is not high. Therefore, reappraisal of ongoing use of bisphosphonates after about 5 years is endorsed by expert consensus, and ‘drug holidays’ should be considered at this time. Further studies are needed to guide clinical practice in this area.  相似文献   
85.
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (= 768 SMV/PR,= 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity.  相似文献   
86.
87.
European Journal of Orthopaedic Surgery & Traumatology - The goals of this study were to compare patient satisfaction and wound-related complications in patients receiving 2-octyl cyanoacrylate...  相似文献   
88.
89.
Graefe's Archive for Clinical and Experimental Ophthalmology - To evaluate the long-term safety and efficacy of intrastromal bevacizumab for treatment of deep corneal neovascularization in...  相似文献   
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号